Black Diamond price target raised to $12 from $11 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Black Diamond Therapeutics (BDTX) to $12 from $11 and keeps a Buy rating on the shares following the Q4 report. The firm expects another clinical update on BDTX-1535 in Q2.